CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Prevalence of Human Papillomavirus Genotypes in High-Grade Cervical Precancer and Invasive Cervical Cancer From Cancer Registries Before and After Vaccine Introduction in the United States
-
10 01 2021
-
-
Source: Cancer. 127(19):3614-3621
Details:
-
Alternative Title:Cancer
-
Personal Author:
-
Description:Background:
US population-based cancer registries can be used for surveillance of human papillomavirus (HPV) types found in HPV-associated cancers. Using this framework, HPV prevalence among high-grade cervical precancers and invasive cervical cancers were compared before and after HPV vaccine availability.
Methods:
Archived tissue from 2 studies of cervical precancers and invasive cervical cancers diagnosed from 1993–2005 (prevaccine) were identified from 7 central cancer registries in Florida; Hawaii; Iowa; Kentucky; Louisiana; Los Angeles County, California; and Michigan; from 2014 through 2015 (postvaccine) cases were identified from 3 registries in Iowa, Kentucky, and Louisiana. HPV testing was performed using L1 consensus polymerase chain reaction analysis. HPV-type–specific prevalence was examined grouped by hierarchical attribution to vaccine types: HPV 16, 18, HPV 31, 33, 45, 52, 58, other oncogenic HPV types, and other types/HPV negative. Generalized logit models were used to compare HPV prevalence in the prevaccine study to the postvaccine study by patient age, adjusting for sampling factors.
Results:
A total of 676 precancers (328 prevaccine and 348 postvaccine) and 1140 invasive cervical cancers (777 prevaccine and 363 postvaccine) were typed. No differences were observed in HPV-type prevalence by patient age between the 2 studies among precancers or invasive cancers.
Conclusions:
The lack of reduction in vaccine-type prevalence between the 2 studies is likely explained by the low number of cases and low HPV vaccination coverage among women in the postvaccine study. Monitoring HPV-type prevalence through population-based strategies will continue to be important in evaluating the impact of the HPV vaccine.
-
Subjects:
-
Source:
-
Pubmed ID:34289090
-
Pubmed Central ID:PMC10084843
-
Document Type:
-
Funding:
-
Volume:127
-
Issue:19
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-124.01 KB]
